Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 100 mg, 150 mg, 200 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Latest News
Summary
- Ojjaara (momelotinib) is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Momelotinib, ruxolitinib, and fedratinib demonstrated comparable efficacy in reducing spleen volume and total symptom scores in patients with myelofibrosis when used as first-line treatments.
- Pacritinib was less effective than ruxolitinib in treating splenomegaly in first-line therapy but appeared effective in second-line treatment after prior ruxolitinib exposure.
- The studies did not explicitly mention differences in effectiveness across specific populations or subgroups.
- Momelotinib demonstrated less toxicity related to erythrocytes and platelets compared to ruxolitinib and fedratinib, with a positive effect on anemia and reduced thrombopenia risk.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ojjaara (momelotinib) Prescribing Information. | 2023 | GlaxoSmithKline LLC., Philadelphia, PA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. | 2021 | Blood Cancer Journal |